Interface Biologics' CSO Paul Santerre receives NSERC Synergy Innovation Award from Governor General

Interface Biologics' CSO Paul Santerre receives NSERC Synergy Innovation Award 
from Governor General 
TORONTO, ONTARIO -- (Marketwire) -- 03/05/13 --  
Editors Note: There is a photo associated with this press release. 
Interface Biologics Inc. (IBI), a privately held commercial stage
developer of transformative biomedical-polymer products, is pleased
to announce that Dr. Paul Santerre, PhD, Chief Scientific Officer at
IBI, was presented with a Synergy Award for Innovation by His
Excellency the Right Honourable David Johnston, Governor General of
Canada during a Natural Sciences and Engineering Research Council of
Canada (NSERC) Awards ceremony at Rideau Hall on February 27th. 
Interface Biologics was founded by Dr. Santerre, and is based on his
groundbreaking work at the University of Toronto's Institute of
Biomaterials and Biomedical Engineering. Together, they have produced
transformative biomedical polymers that improve the biocompatibility
of medical devices, making them safer and more effective. Last year,
IBI's licensing partner, Angiodynamics, received FDA Clearance for
BioFlo(TM) PICC with IBI's Endexo(TM) technology. 
"The Synergy Awards for Innovation recognize outstanding achievements
that have resulted from partnerships between university researchers
and industry," said Suzanne Fortier, President of NSERC. "These
awards honour collaboration as the foundation of achievement and
highlight Canadian innovations." The NSERC Synergy Awards include
money for a research grant as well as funding to hire an NSERC
Industrial R&D Fellow for two years.  
"We are honoured to have been selected by NSERC for this prestigious
Synergy Award. We continue to develop biomedical polymer technologies
that can be applied to a myriad of clinical applications and this
award is recognition of the winning partnership between Professor
Santerre, the University of Toronto, Interface Biologics and our
commercial licensees. In conjunction with Professor Santerre and his
lab, we will be using the proceeds from the grant to continue to
develop innovative technologies that can increase the safety and
effectiveness of medical devices," commented Tom Reeves, President
and CEO of Interface Biologics.  
"Investing in science and technology has a direct impact on
Canadians," said the Honour
able Gary Goodyear, Minister of State
(Science and Technology). "The achievements of the top researchers
honoured today, and the successful partnerships they have forged with
the business community, demonstrate how our investments in research
create high-value jobs and help build a stronger, more prosperous
country." 
About Interface Biologics Inc. 
Interface Biologics (IBI) is an early commercial stage privately held
company that develops transformative biomedical polymer technology to
improve the safety and effectiveness of medical devices. IBI's
primary technology focus areas are anti-thrombogenic devices that
reduce thrombosis and programmable combination drug delivery devices.
For more information about Interface Biologics, please visit
www.interfacebiologics.com. 
To view the photo associated with this press release, please visit
the following link:
http://www.marketwire.com/library/20130304-IBimageLG.jpg.
Image Available:
http://www.marketwire.com/library/20130304-IBimageLG.jpg 
Contacts:
Hageman Communications
Julie Fotheringham
Partner
416-951-7988
Julie.fotheringham@hageman.ca
 
 
Press spacebar to pause and continue. Press esc to stop.